Curaleaf Strikes Back at Aurora Board Over Rejected US$5.00 Hostile Bid
CURLF sits 41% above its 52-week low of $5.4.
Summary
Curaleaf publicly rebutted Aurora's October 14 rejection of its enhanced US$5.00 hostile bid, arguing that Aurora is obstructing the only binding offer while giving rivals diligence access. The tender deadline is December 4, 2026.
Updates
· SEC 425 — On October 19, 2026, Curaleaf said its enhanced offer implies a 14.3x 2026 Adjusted EBITDA multiple for Aurora, higher than Curaleaf's 13.7x (IFRS), and a 217% ex-cash premium.
- EBITDA Trend — Aurora's Adjusted EBITDA declined 63% from the previous two quarters over its two most recent quarterly results.
- ATM Share Sales — Aurora sold shares under its ATM program without any price limit, at prices as low as $2.60 per share in July 2026; the $5.00 offer is a 92% premium to that level.
- Analyst Views — ATB Capital Markets wrote on October 6 that the revised bid is favorable for Aurora shareholders and offers more than the fair value of Aurora as a standalone. Seaport Research Partners wrote on October 15 questioning why Aurora would give other potential buyers due diligence access while refusing to engage with Curaleaf.
- Fairness Opinion Concerns — Aurora's own financial advisor concluded that Curaleaf's trading price can be reasonably regarded as a proxy for underlying value. In most deals a special committee gets a second fairness opinion from a truly independent advisor; Aurora has not done that, and Fort Capital disclosed no supporting analysis for its conclusion.
- Process and Conditions — Aurora's Special Committee is actively soliciting third-party bidders under the same market conditions it calls opportunistic for Curaleaf. Curaleaf's bid is subject to market standard conditions, and Aurora has not engaged with Curaleaf on deal terms at any point.
- Reimbursement Rate — The Canadian medical reimbursement rate change only affected Aurora's most recent quarter, not both of the last two quarters.
All 10 details
- Aurora's Adjusted EBITDA declined 63% from the previous two quarters over its two most recent quarterly results.
- Aurora's own financial advisor concluded in its opinion that the trading price of Curaleaf shares can be reasonably regarded as a proxy for their underlying value.
- ATB Capital Markets wrote on October 6: "We believe the revised bid is favorable for Aurora shareholders and offers more than the fair value of Aurora as a standalone."
- Seaport Research Partners wrote on October 15: "We also question why ACB is willing to provide other potential buyers access to due diligence while refusing to engage with CURLF, particularly if its goal is to maximize shareholder value."
- Aurora's Special Committee is actively soliciting third-party bidders under the exact same market conditions it says make Curaleaf's offer opportunistic.
- Curaleaf's bid is subject to market standard conditions, and Aurora has not engaged with Curaleaf on deal terms at any point in this process.
- In most deals, a special committee gets a second fairness opinion from a truly independent advisor; Aurora has not done that.
- Fort Capital did not provide or disclose any supporting analysis to Aurora shareholders of its stated conclusion.
- Aurora sold shares under its ATM program without any price limit, at prices as low as $2.60 per share in July 2026; the $5.00 offer is a 92% premium to that level.
- The Canadian medical reimbursement rate change only affected Aurora's most recent quarter, not both of the last two quarters.
Key Events · M&A and Partnerships · CURLF
-
Curaleaf Rebuts Aurora Rejection
On October 19, 2026, Curaleaf responded to Aurora's October 14 Notice of Change, in which Aurora's board again recommended that shareholders reject Curaleaf's enhanced US$5.00-per-share hostile bid.
-
Offer Premium Quantified
Curaleaf states that the enhanced offer represents an 86% premium to Aurora's unaffected 30-day VWAP and 217% on an ex-cash basis, and notes that Aurora sold ATM shares as low as US$2.60 in July 2026.
-
Diligence Access Dispute
According to Curaleaf, Aurora has signed confidentiality and standstill agreements with unnamed parties examining its information while continuing to deny Curaleaf diligence access.
-
Advisor Independence Questioned
Curaleaf flags that Aurora advisor Fort Capital's fees may be contingent on an alternative transaction or no transaction, and that no supporting analysis was disclosed.
Analysis · CURLF · Life Sciences
The proxy fight for Aurora is escalating. After Aurora's board again urged shareholders on October 14 to reject the enhanced US$5.00-per-share offer, Curaleaf is pressing its case in public. No new bid terms appear in the filing, but it puts fresh pressure points on the record: Aurora is granting diligence access to unnamed parties while locking out the only binding bidder, and its financial advisor Fort Capital may be paid contingent on an alternative or no deal. Curaleaf also quantifies the offer at an 86% premium to Aurora's unaffected 30-day VWAP and 217% on an ex-cash basis, and points to Aurora's own ATM sales as low as US$2.60 in July 2026. With the tender deadline running to December 4, 2026, the outcome still hinges on whether Aurora's board engages or shareholders tender into the offer.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 37.9% of the 895 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CURLF was trading at $7.63 on OTC in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $5.40 to $15.15. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.